Title:
DUAL OX40 AGONIST/IL-2 CANCER THERAPY METHODS
Document Type and Number:
WIPO Patent Application WO/2013/130102
Kind Code:
A3
Abstract:
OX40 is a potent immune stimulating target. Provided herein is a method of treating cancer, which includes administering to a subject in need of treatment an OX40 agonist and a common gamma chain (yc) cytokine or an active fragment, variant, analog, or derivative thereof In certain aspects the common gamma chain (yc) cytokine is interleukin-2 (IL-2) or an active fragment, variant, analog, or derivative thereof. Combined treatment with an agonist anti-OX40 mAb and IL-2 synergized to augment tumor immunotherapy against multiple tumor types. Dual therapy was also able to restore the function of anergic tumor-reactive CD8+ T cells.
Inventors:
REDMOND WILLIAM (US)
WEINBERG ANDY (US)
WEINBERG ANDY (US)
Application Number:
PCT/US2012/027496
Publication Date:
April 17, 2014
Filing Date:
March 02, 2012
Export Citation:
Assignee:
PROVIDENCE HEALTH & SERVICES OREGON (US)
REDMOND WILLIAM (US)
WEINBERG ANDY (US)
REDMOND WILLIAM (US)
WEINBERG ANDY (US)
International Classes:
A61K39/395; A61K38/20
Foreign References:
| US20110033449A1 | 2011-02-10 | |||
| US20030040477A1 | 2003-02-27 | |||
| US20110008368A1 | 2011-01-13 |
Other References:
See also references of EP 2819693A4
Attorney, Agent or Firm:
HAANES, Elizabeth, J. et al. (P.L.L.C.1100 New York Avenue, N, Washington DC, US)
Download PDF: